Mostra i principali dati dell'item

dc.creatorNasi A., McArdle S., Gaudernack G., Westman G., Melief C., Rockberg J., Arens R., Kouretas D., Sjölin J., Mangsbo S.en
dc.date.accessioned2023-01-31T09:03:41Z
dc.date.available2023-01-31T09:03:41Z
dc.date.issued2020
dc.identifier10.1016/j.toxrep.2020.06.003
dc.identifier.issn22147500
dc.identifier.urihttp://hdl.handle.net/11615/76922
dc.description.abstractDuring the current COVID-19 pandemic, a need for evaluation of already available drugs for treatment of the disease is crucial. Hereby, based on literature review from the current pandemic and previous outbreaks with corona viruses we analyze the impact of the virus infection on cell stress responses and redox balance. High levels of mortality are noticed in elderly individuals infected with SARS-CoV2 and during the previous SARS-CoV1 outbreak. Elderly individuals maintain a chronic low level of inflammation which is associated with oxidative stress and inflammatory cytokine production, a condition that increases the severity of viral infections in this population. Coronavirus infections can lead to alterations of redox balance in infected cells through modulation of NAD + biosynthesis, PARP function along with altering proteasome and mitochondrial function in the cell thereby leading to enhanced cell stress responses which further exacerbate inflammation. ROS production can increase IL-6 production and lipid peroxidation resulting in cell damage. Therefore, early treatment with anti-oxidants such as NAC during COVID-19 can be a way to bypass the excessive inflammation and cell damage that lead to severe infection, thus early NAC as intervention should be evaluated in a clinical trial setting. © 2020 The Authorsen
dc.language.isoenen
dc.sourceToxicology Reportsen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85086894523&doi=10.1016%2fj.toxrep.2020.06.003&partnerID=40&md5=468c9d26248127bb390cce5617922aea
dc.subjectacetylcysteineen
dc.subjectangiotensin converting enzyme 2en
dc.subjectC reactive proteinen
dc.subjectcryopyrinen
dc.subjectgroup 2d secretory phospholipase a2en
dc.subjectinflammasomeen
dc.subjectinterferonen
dc.subjectinterleukin 6en
dc.subjectneutrophil cytosol factor 1en
dc.subjectnicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferaseen
dc.subjectpeptides and proteinsen
dc.subjectproteasomeen
dc.subjectreactive oxygen metaboliteen
dc.subjectreduced nicotinamide adenine dinucleotide phosphate oxidaseen
dc.subjecttoll like receptor 4en
dc.subjecttryptophan 2,3 dioxygenaseen
dc.subjecttumor necrosis factoren
dc.subjectunclassified drugen
dc.subjectagingen
dc.subjectArticleen
dc.subjectcell stressen
dc.subjectcoronavirus disease 2019en
dc.subjectcytokine productionen
dc.subjectcytokine releaseen
dc.subjecthomeostasisen
dc.subjecthumanen
dc.subjectimmune responseen
dc.subjectinnate immunityen
dc.subjectmortalityen
dc.subjectnonhumanen
dc.subjectoxidation reduction reactionen
dc.subjectoxidative phosphorylationen
dc.subjectpriority journalen
dc.subjectprotein expressionen
dc.subjectSevere acute respiratory syndrome coronavirus 2en
dc.subjectviremiaen
dc.subjectElsevier Inc.en
dc.titleReactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic interventionen
dc.typejournalArticleen


Files in questo item

FilesDimensioneFormatoMostra

Nessun files in questo item.

Questo item appare nelle seguenti collezioni

Mostra i principali dati dell'item